COVID-19: For information related to COVID-19 (formerly referred to as “novel coronavirus"), visit

VCU Massey Cancer Center


2016 Archive

Bernard Fuemmeler named Massey’s associate director for cancer prevention and control

VCU Massey Cancer Center welcomes Bernard Fuemmeler, Ph.D., M.P.H., as the associate director for cancer prevention and control. A clinical health psychologist and epidemiologist, he joined the VCU School of Medicine as a professor in the Department of Health Behavior and Policy in June 2016. 

Continue reading →

Paul Dent for blog

Two clinical trials test novel combination therapies for brain and central nervous system cancers

Researchers at VCU Massey Cancer Center are conducting two clinical trials testing novel combination therapies for the treatment of brain and central nervous system cancers. The phase 1 and phase 2 clinical trials are both based on translational research performed at Massey by Paul Dent, Ph.D., Universal Corporation Chair in Cancer Cell Signaling and member of the Cancer Cell Signaling research program at VCU Massey as well as professor of biochemistry and molecular biology at VCU School of Medicine. 

Continue reading →

Clinical trial tests promising immunotherapies for advanced lung cancer

Sherman Baker Jr., M.D., medical oncologist and member of the Developmental Therapeutics research program at VCU Massey Cancer Center, is spearheading a phase 3 clinical trial testing two immunotherapy drugs, MEDI4736 and tremelimumab, for the treatment of patients with advanced lung cancer. The goal of the study is to determine whether MEDI4736 combined with tremelimumab or MEDI4736 by itself is more effective than traditional chemotherapy treatment to treat advanced lung cancer.

Continue reading →

Massey researcher awarded $3 million to study the effect of blood cell stimulation on the development of adolescent leukemia and bone marrow disorders

Massey program leader, researcher and physician Seth Corey M.D., M.P.H., was awarded more than $3 million in grant funding from the National Heart, Lung and Blood Institute (NHLBI) for a four-and-a-half-year study on the evolution of a blood cell deficiency to pre-leukemia. The research aims to determine whether a common treatment for the condition acts as a contributor to the development of leukemia or other life-threatening bone marrow disorders.

Continue reading →

A second first birthday

Six months after her original cancer diagnosis, Ann Moore sat in a clinic exam room anticipating the results from her CT scan. In February 2015, she had received the last of 18 weeks worth of chemotherapy treatment for stage IV ovarian cancer, and now waited anxiously to hear if it had been effective.

Continue reading →